Biocon Biologics Ltd. (BBL), a global leader in biosimilars and a subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), has announced a key settlement and license agreement with Amgen Inc., paving the way for the U.S. commercialization of its biosimilars Bosaya™ and Aukelso™.
Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq) are biosimilars to Amgen’s Prolia® and Xgeva®, respectively. Bosaya™ is available as a 60 mg/mL injection in a single-dose prefilled syringe, while Aukelso™ comes as a 120 mg/1.7 mL injection (70 mg/mL for subcutaneous use in a single-dose vial). Both treatments target osteoporosis and cancer-related bone conditions, offering patients more accessible therapeutic options.
The settlement agreement resolves ongoing patent litigation at the United States District Court for the District of New Jersey, allowing Biocon Biologics to officially launch Bosaya™ and Aukelso™ in the U.S. starting October 1, 2025. Terms of the agreement remain confidential.
This development strengthens Biocon Biologics’ footprint in the U.S. biosimilars market and reinforces its commitment to expanding patient access to affordable, high-quality therapies globally.